Pfizer and BioNTech to start human trials of Covid-19 vaccine
Tests will be on 200 healthy people in the first stage of the trial as drug companies around the world race to find a vaccine
Berlin —Pfizer and BioNTech have secured approval for Germany’s first human clinical trials of a possible coronavirus vaccine, entering a global race to develop a defence against the pandemic.
Regulators gave the green light to test the companies’ proposed vaccine on 200 healthy people aged 18 to 55 years in a first stage, and on additional high-risk candidates in a second stage, according to a statement on Wednesday. Shares of BioNTech rose as much as 63% in Frankfurt...